Fondazione del Piemonte per l’Oncologia – I.R.C.C.S.
SP142 km 3,95, SP142, km 3,95
10060 Candiolo NO
Contact: James M. Hughes, Ph.D.
Role: Responsable of TTO
E-mail: segreteria.direzioneamministrativa@ircc.it
Website: www.https://www.irccs.org/
Number of employees: 640
Year of establishment: 2008
Who we are
The Fondazione del Piemonte per l’Oncologia (FPO), known as the Candiolo Cancer Institute, is a center of excellence dedicated to cancer research, diagnosis, and treatment. It is accredited by the Italian Ministry of Health as an IRCCS (Institute for Scientific Research and Healthcare). Located in Candiolo, near Turin, our institution is a national and international reference center with a long-standing commitment to the fight against cancer.
Founded to drive innovation in oncology, FPO-IRCCS integrates cutting-edge scientific research with high-quality clinical care within a single institution. Through collaborations with universities, research institutes, and industrial partners, we have created an environment where scientific discoveries are rapidly translated into clinical applications. Our mission is to improve patients’ quality of life by providing personalized treatments based on the latest scientific evidence.
With over 600 professionals and a growing portfolio of research projects, FPO-IRCCS continues to be a symbol of excellence in the Italian oncology landscape.
What we do
At FPO-IRCCS, we offer a comprehensive range of services and activities covering the entire spectrum of cancer care. Our expertise includes molecular diagnostics, innovative medical treatments, advanced radiotherapy, and high-precision robotic oncologic surgery, alongside a strong commitment to personalized medicine.
Beyond clinical care, our institute is distinguished by its translational research, which focuses on transforming scientific discoveries into new therapeutic approaches. In particular, we work on emerging technologies such as biomarkers, cell therapies, and innovative diagnostic solutions.
Our services are available to patients from across Italy and abroad, ensuring a multidisciplinary approach that combines medical expertise, patient-centered care, and state-of-the-art technologies. Our network of collaborations enables us to provide treatments that not only extend life expectancy but also enhance the quality of life for cancer patients.
